wayground logo

Free Printable Worksheets

NEW

Font size

S
M
L
XL
Worksheets

CLPT, M.Pharmacy, Pharmaceutics; Regulatory Affairs

Total questions: 30

Worksheet time: 30mins

Name
Class
Date
1.

Select the responsibility/s of Regulatory Affairs personnel

a)

To analyze the content of the active ingredient in the formulation

b)

Work with federal, state and local governing agencies to get the approval for drug

c)

To undertake stability studies of the drug products

d)

To supervise the production of the formulation

2.

What Are The Goals Of Regulatory Affairs Professionals?

a)

Protection of human health

b)

Ensuring safety, efficacy and quality of drugs

c)

Ensuring appropriateness and accuracy of product information

d)

Above all

3.

What Are The Roles Of Regulatory Affairs Professionals?

a)

Preparation of organized and scientifically valid NDA, ANDA, IND, DMF submissions.

b)

Ensure adherence and compliance with all the applicable cGMP, ICH, GCP, GLP guidelines, regulations and laws.

c)

Providing expertise and regulatory intelligence in translating regulatory requirements into practical workable plans.

d)

Above all

4.

IND is an application which is filed with FDA to get approval for legally testing an experimental drug on human subjects in the USA.

a)

True

b)

False

5.

BCS classification for Class III drugs is

a)

High solubility high permeability

b)

Low solubility high permeability

c)

High solubility low permeability

d)

Low solubility Low permeability

6.

Animal studies, clinical trials, bioavailability studies are part of which application process

a)

IND

b)

NDA

c)

ANDA

d)

BLA

7.

Type II DMF deals with

a)

Packaging materials

b)

Manufacturing Site

c)

Drug substance

d)

Excipients

8.

It is an application for the approval of Generic Drugs

a)

NDA

b)

BLA

c)

IND

d)

ANDA

9.

Important facts regarding DMFs :

a)

It is submitted to FDA to provide confidential information

b)

Its submission is not required by law or regulations

c)

It is neither approved nor disapproved

d)

Above all

10.

On average, it takes ____________ years to do the discovery research and testing to bring a new drug to the market.

a)

6-9

b)

9-12

c)

12-15

d)

15-18

11.

What is the major trigger of clinical study delays?

a)

Budget concerns

b)

FDA hold-ups

c)

Recruitment problems

d)

Safety/toxicity issues

12.

What is the term for the process that is used to prove that a drug is safe and effective in treating specific conditions in certain patient populations?

a)

Drug discovery

b)

Preclinical development

c)

The patent process

d)

Clinical development

13.

Which department is not primarily involved with the creation of the package insert?

a)

Marketing

b)

Clinical Development

c)

Business Development

d)

Regulatory Affairs

14.

Most pharma companies have a regulatory affairs function that acts as their liaison between the company and the FDA during the clinical trial process.

a)

True

b)

False

15.

When does a company seek permission to market a product in the US?

a)

Following the completion of Phase 1

b)

Following the completion of Phase 2

c)

Following the completion of Phase 3

d)

Following the completion of Phase 4

16.

IND' means

a)

Investigational novel drug application

b)

Investigational new dose application

c)

Investigational new drug application

d)

None

17.

The requirements for the format and content of the IND application, as well as the requirements governing the use of the IND, are provided in ........................

a)

21 CFR, 315

b)

21 CFR, 316

c)

21 CFR, 314

d)

21 CFR, 312

18.

In USA, applicant can start the Phase 1 clinical trials without approval of IND application.

a)

True

b)

False

19.

Form FDA 1571 is part of IND application.

a)

True

b)

False

20.

IND application do not contain 'Investigator's brochure'

a)

True

b)

False

21.

Chemistry, manufacturing, and control data is not required to submit along with the IND application.

a)

True

b)

False

22.

Pharmacology and toxicology data is also part of IND application.

a)

True

b)

False

23.

Institutional review board data information is not required while submitting the IND application.

a)

True

b)

False

24.

'NDA' means:

a)

New dose application

b)

New drug applicant

c)

New drug application

d)

None

25.

In USA, NDA has to be submitted using ............

a)

eCTD

b)

CTD

c)

Paper

d)

NeeS

26.

NDA 'Standard review' time ...............

a)

12 months

b)

6 months

c)

3 months

d)

8 months

27.

NDA 'Priority review' time ...............

a)

12 months

b)

6 months

c)

3 months

d)

8 months

28.

eCTD submission gateway for NDA ...............

a)

web client

b)

e-Submission gateway and the web client

c)

Electronic Submissions Gateway

d)

None

29.

NDA Application fee for single application Aprox. ................

a)

$ 3,421,495

b)

$ 2,421,495

c)

$ 1,421,495

d)

$ 4,421,495

30.

NDA is approved only by USFDA

a)

True

b)

False